Dana-Farber Cancer Institute | Strategic Alliance Partners

Drs Matulonis and Esselen explore the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes.

Drs Rotow and Dietrich discuss the significance of the accelerated FDA approval of zongertinib (Hernexeos) for patients with HER2 TKD–mutated NSCLC.

PANGEA-SMM outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

A detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas.

Toni K. Choueiri, MD, discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study.

Toni K. Choueiri, MD, discusses new data with adjuvant belzutifan plus pembrolizumab for the treatment of patients with clear cell RCC.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Toni K. Choueiri, MD, discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

Read a refresh of the top FDA news in breast cancer from February 2026, including upcoming decision dates, a fast-tracked drug, and REMS safety updates.

Sarah Sammons, MD, discusses efficacy data from a phase 2 study of pumitamig in patients with locally advanced or metastatic triple-negative breast cancer.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

Dr Sammons discusses the rationale for and findings from a phase 2 study evaluating pumitamig in patients with locally advanced or metastatic TNBC.

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology, bringing together leading cancer researchers and clinicians.

Research showed that an oncolytic virus could prolong survival in patients with glioblastoma.

PATINA shows palbociclib added to anti-HER2 plus endocrine maintenance prolongs progression-free survival by 15+ months in HR+, HER2+ metastatic breast cancer.

Drs Matulonis and Porter discuss the role of immunotherapy in gynecologic cancer management, focusing on clinical breakthroughs and future directions.

Nicholas Polizzi, PhD, and Edward Boyden, PhD, are recipients of the December 2025 Medical Research Grant from the W. M. Keck Foundation.

A global analysis led by Dana-Farber combined patient data from 6 major clinical trials to compare 2 immunotherapies for advanced non–small cell lung cancer.

Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.

Extending endocrine therapy beyond 5e years significantly reduces relapse risk in young women with HR-positive early-stage breast cancer.

Erica L. Mayer, MD, MPH, discusses updated data with CDK4/6 inhibitors and ongoing investigations of oral SERDs in HR-positive breast cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Guilherme Nader-Marta, MD, and Erica L. Mayer, MD, MPH, discusses innovative treatments for HR-positive, HER2-negative metastatic breast cancer.

Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.